The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Takashi Seto
No relevant relationships to disclose
Taito Esaki
No relevant relationships to disclose
Fumihiko Hirai
No relevant relationships to disclose
Shuji Arita
No relevant relationships to disclose
Kaname Nosaki
No relevant relationships to disclose
Akitaka Makiyama
No relevant relationships to disclose
Takuro Kometani
No relevant relationships to disclose
Chinatsu Fujimoto
No relevant relationships to disclose
Motoharu Hamatake
No relevant relationships to disclose
Hiroaki Takeoka
No relevant relationships to disclose
Felix Agbo
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Xiaojin Shi
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca